Search the Newsreel

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044

Vanda Pharmaceuticals is set to launch BYSANTI in the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with patent protection extending until May 2044. The company also reported strong Q2 Fanapt sales growth and has several late-stage pipeline readouts …

Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong second-quarter 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increase signals management's confidence in XDEMVY's commercial trajectory, though the company still faces risks associated …

Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next

Ascendis Pharma A/S reported strong Q2 results, with revenues beating expectations by 2.8% and statutory profit exceeding forecasts by 104%. Analysts have subsequently upgraded their EPS estimates for 2026, though the consensus price target remains unchanged at US$310. The company is expected to continue …

612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC

SCS Capital Management LLC acquired 612,850 shares of Agios Pharmaceuticals (NASDAQ:AGIO) during the second quarter, valued at approximately $22.7 million. The biopharmaceutical company reported a quarterly loss per share of $1.69, missing estimates, but exceeded revenue expectations with $44.75 million. Analyst sentiment for AGIO …

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

S&CO Inc. Buys Shares of 358,302 Royalty Pharma PLC $RPRX

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal

BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

Marksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …

Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?

Teva Pharmaceutical Industries (TEVA) has initiated a phase 2b trial for its anti IL-15 antibody TEV-'408 for nonsegmental vitiligo, following promising phase 1b results. This development, coupled with a significant 1-year share price return of 105.88%, has renewed investor interest. While the stock is …

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …

ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold

ANI Pharmaceuticals (ANIP) is currently in focus after reporting its Q2 and H1 2026 results and reaffirming its full-year net revenue outlook of $1,080 million to $1,140 million. Despite recent strong earnings, the stock has seen a short-term decline, though it shows significant long-term …

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past …

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …

Eton Pharmaceuticals Stock Soars After Huge Q2 Beat And Target Hikes

Eton Pharmaceuticals (ETON) stock surged by 45.78% after reporting a significant Q2 beat, with non-GAAP EPS of $0.43 and revenue of $37.6M, driven by 99% year-over-year growth. The company also raised its 2026 revenue guidance to over $145M and adjusted EBITDA margin to at …

Eton Pharmaceuticals Soars After Blowout Q2 And Guidance Hike

Eton Pharmaceuticals (NASDAQ: ETON) experienced a significant stock surge of over 45% after reporting blowout Q2 earnings and raising its 2026 revenue guidance. The company's Q2 non-GAAP EPS and revenue significantly beat consensus estimates, driven by strong growth and the successful relaunch of Hemangeol. …

Will Aurinia’s Reaffirmed 2026 Guidance and Large Buyback Reshape Aurinia Pharmaceuticals' (AUPH) Narrative?